Described are fatty acids with one or more unsaturations, having an odd hydrocarbon chain, the fatty acids having the chemical structure of the therapeutically active metabolites of even-chain mono- or polyunsaturated alpha-hydroxylated fatty acids. Also described are compositions comprising said fatty acids, medical uses thereof, and the use thereof as indicators of the efficacy of and/or response to the treatment of a patient with the even-chain mono- or polyunsaturated alpha-hydroxylated fatty acids from which they are derived.

A nutritional supplement composition that enhances the incorporation of calcium and other bone building elements in bone and that prevents bone breakdown, specifically due to the chronic metabolic acidosis that the typical Western diet generates each day. The transcription factor NFKB (Nuclear Factor Kappa B), which underlies some of this physiology, has also been shown to adversely affect fat metabolism. The enzymatic protein complex, AMP Kinase (Adenosine Monophosphate Kinase), a key regulator of energy metabolism, has been shown to reverse the effects of excessive NFKB activity on bone and fat metabolism. The novel nutrients modulate nutrient partitioning and fat metabolism in a human or animal so as to increase oxidation of fat, decrease storage of fat and promote increased storage of glycogen. They are composed of one or more of nutrients selected from the group consisting of Hesperidin, Berberine, Epigallocatechin 3-Gallate (EGCG), Resveratrol, Curcumin, Ginsenosides, Gingerols, Hispidulin, Honokiol, Magnolol and Quercetin. A method for modulating nutrient partitioning in a human involves orally or parenterally administering the aforementioned composition to the human or animal, preferably on a daily basis, for a therapeutically effective period of time. Preferably, the method further involves having the recipient follow a specific dietary regimen wherein the glycemic index is less than 60 and the daily calorie consumption from carbohydrates is less than about 50% and the daily calorie consumption from protein is at least about 20%. Optionally, the method further involves an exercise program, a stress reduction program and/or a blood donation program.

A nutritional supplement composition that enhances the incorporation of calcium and other bone building elements in bone and that prevents bone breakdown, specifically due to the chronic metabolic acidosis that the typical Western diet generates each day. The transcription factor NFKB (Nuclear Factor Kappa B), which underlies some of this physiology, has also been shown to adversely affect fat metabolism. The enzymatic protein complex, AMP Kinase (Adenosine Monophosphate Kinase), a key regulator of energy metabolism, has been shown to reverse the effects of excessive NFKB activity on bone and fat metabolism. The novel nutrients modulate nutrient partitioning and fat metabolism in a human or animal so as to increase oxidation of fat, decrease storage of fat and promote increased storage of glycogen. They are composed of one or more of nutrients selected from the group consisting of Hesperidin, Berberine, Epigallocatechin 3-Gallate (EGCG), Resveratrol, Curcumin, Ginsenosides, Gingerols, Hispidulin, Honokiol, Magnolol and Quercetin. A method for modulating nutrient partitioning in a human involves orally or parenterally administering the aforementioned composition to the human or animal, preferably on a daily basis, for a therapeutically effective period of time. Preferably, the method further involves having the recipient follow a specific dietary regimen wherein the glycemic index is less than 60 and the daily calorie consumption from carbohydrates is less than about 50% and the daily calorie consumption from protein is at least about 20%. Optionally, the method further involves an exercise program, a stress reduction program and/or a blood donation program.

Disclosed are methods for inhibiting cellular dysfunctionality and subsequent cell death due to cellular accumulation of oxidized polyunsaturated fatty acids (PUFAs) products wherein said accumulation is mediated, at least in part, by impaired enzymatic process(es) that are responsible for neutralizing said oxidized products.

Disclosed are methods for inhibiting cellular dysfunctionality and subsequent cell death due to cellular accumulation of oxidized polyunsaturated fatty acids (PUFAs) products wherein said accumulation is mediated, at least in part, by impaired enzymatic process(es) that are responsible for neutralizing said oxidized products.

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

A method to treat the skin condition vitiligo is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol, at a concentration of 3%-20% by weight of the composition onto the affected skin area of a subject in need thereof. Application may be twice (2) daily for about six (6) weeks. Cannabidiol and cannabigerol may be sourced naturally or synthetically.

A method to treat the skin condition vitiligo is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol, at a concentration of 3%-20% by weight of the composition onto the affected skin area of a subject in need thereof. Application may be twice (2) daily for about six (6) weeks. Cannabidiol and cannabigerol may be sourced naturally or synthetically.

A pharmaceutical composition or a cosmetic composition for treating hair loss, or promoting hair growth is described. The composition according to the present invention exhibits an excellent effect of treating hair loss and promoting hair growth, and can be safely used regardless of sex and age.